Evidence map›Paper›PMID 26924054›Full record

ArticleKidney international2016

Complement receptor 3 mediates renal protection in experimental C3 glomerulopathy.

Thomas D Barbour, Guang Sheng Ling, Marieta M Ruseva, Liliane Fossati-Jimack, H Terence Cook, Marina Botto, Matthew C Pickering

Open access · hybridAbstract read
In one paragraph

Article in Kidney international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Thomas D BarbourCentre for Complement and Inflammation Research, Imperial College, London, UK.
Guang Sheng LingCentre for Complement and Inflammation Research, Imperial College, London, UK.
Marieta M RusevaCentre for Complement and Inflammation Research, Imperial College, London, UK.
Liliane Fossati-JimackCentre for Complement and Inflammation Research, Imperial College, London, UK; Centre for Experimental Medicine and Rheumatology, Queen Mary University of London, London, UK.
H Terence CookCentre for Complement and Inflammation Research, Imperial College, London, UK.
Marina BottoCentre for Complement and Inflammation Research, Imperial College, London, UK.
Matthew C PickeringCentre for Complement and Inflammation Research, Imperial College, London, UK. Electronic address: matthew.pickering@imperial.ac.uk.
Imperial College London · GBCentre for Inflammation Research · GBQueen Mary University of London · GB

Funding

Wellcome TrustWellcome Trust WT082291MA
6 · The paper itself

Abstract

C3 glomerulopathy is a complement-mediated renal disease that is frequently associated with abnormalities in regulation of the complement alternative pathway. Mice with deficiency of factor H (Cfh(-/-)), a negative alternative pathway regulator, are an established experimental model of C3 glomerulopathy in which complement C3 fragments including iC3b accumulate along the glomerular basement membrane. Here we show that deficiency of complement receptor 3 (CR3), the main receptor for iC3b, enhances the severity of spontaneous renal disease in Cfh(-/-) mice. This effect was found to be dependent on CR3 expression on bone marrow-derived cells. CR3 also mediated renal protection outside the setting of factor H deficiency, as shown by the development of enhanced renal injury in CR3-deficient mice during accelerated nephrotoxic nephritis. The iC3b-CR3 interaction downregulated the proinflammatory cytokine response of both murine and human macrophages to lipopolysaccharide stimulation in vitro, suggesting that the protective effect of CR3 on glomerular injury was mediated via modulation of macrophage-derived proinflammatory cytokines. Thus, CR3 has a protective role in glomerulonephritis and suggests that pharmacologic potentiation of the macrophage CR3 interaction with iC3b could be therapeutically beneficial.

Indexed as

AnimalsCD11b AntigenComplement C3Complement Factor HCytokinesDisease Models, AnimalFemaleGlomerulonephritisGlomerulonephritis, MembranoproliferativeHereditary Complement Deficiency DiseasesKidney DiseasesMacrophage-1 AntigenMice, Inbred C57BLMyeloid CellsCD11b AntigenComplement C3Complement Factor HCytokinesMacrophage-1 Antigencomplementglomerulonephritismacrophages

Identifiers

PMID26924054
PMCPMC4869622
OpenAlexW2272680742

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.